A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma

Cancer

Volumn 80, Issue 7, 1997, Pages 1179-1187

  Machover, David ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

5 fluorouracil; Advanced colorectal carcinoma; Biomodulation; Chemotherapy; Folinic acid; Leucovorin; Metastatic colorectal carcinoma

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CARCINOMA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL RESPONSE MODIFIERS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; LEUCOVORIN; LYMPHATIC METASTASIS;

EID: 0030931974     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971001)80:7<1179::AID-CNCR1>3.0.CO;2-G     Document Type: Review

References (47)

1. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H. Trends in cancer incidence and mortality. IARC Sci Publ 1993;121:1-806.
2. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995;45:8-30.
3. Chu KC, Tarone RE, Chow WH, Hankey BF, Ries LA. Temporal patterns in colorectal cancer incidence, survival, and mortality from 1950 through 1990. J Natl Cancer Inst 1994; 86:997-1006.
4. Dukes CE. The surgical pathology of rectal cancer. J Clin Pathol 1949;2:95-9.
5. Turnbull RB Jr., Kyle K, Watson FR, Spratt J. Cancer of the colon: the influence of the no-touch isolation technique on survival rates. Ann Surg 1967;166:420-7.
6. Gabriel WB, Dukes C, Bussey HJR. Lymphatic spread in cancer of the rectum. Br J Surg 1935;23:395-413.
7. Heidelberg C, Chaudhuari NK, Danenberg P, Mooren D, Griesbach L, Duschinsky R, et al. Fluorinated pyrimidines: a new class of tumor inhibitory compounds. Nature 1957;179:663-6.
8. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
9. Milano G, Etienne MC, Renee N, Thyss A, Schneider M, Ramioli A, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1994;12:1291-5.
10. Santi DV, McHenry CS, Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974;13:471-81.
11. Danenberg PV, Lockshin A. Fluorinated pyrimidines as tight-binding inhibitors of thymidylate synthetase. Pharmacol Ther 1981:13:69-90.
12. Drake JC, Voeller DM, Allegra CJ, Johnston PG. The effect of dose and interval between 5-fluorouracil and leucovorin on the formation of thymidylate synthase ternary complex in human cancer cells. Br J Cancer 1995;71:1145-50.
13. Houghton JA, Williams LG, de Graaf SS, Cheshire PJ, Rodman JH, Maneval DC, et al. Relationship between dose rate of [6RS] Leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts. Cancer Res 1990;50:3493-502.
14. Houghton JA, Williams LG, Loftin SK, Cheshire PJ, Morton CL, Houghton PJ, et al. Factors that influence the therapeutic activity of 5-fluorouracil [6RS] leucovorin combinations in colon adenocarcinoma xenografts. Cancer Chemother Pharmacol 1992;30:423-32.
15. Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1985;260:9720-6.
16. Radparvar S, Houghton PJ, Houghton JA. Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2′-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft. Biochem Pharmacol 1989;38:335-42.
17. Boarman DM, Allegra CJ. Intracellular metabolism of 5-formyl tetrahydrofolate in human breast and colon cell lines. Cancer Res 1992;52:36-44.
18. Cao S, Frank C, Rustum YM. Role of fluoropyrimidine schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma. J Natl Cancer Inst 1996;88:430-6.
19. Houghton JA, Williams LG, Cheshire PJ, Wainer IW, Jadaud P, Houghton PJ. Influence of dose of [6 RS] leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts. Cancer Res 1990;50:3940-6.
20. Erlichman C, Fine S, Wong A, Elhakim T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988;6:469-75.
21. Poon MA, O'Connell, MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-18.
22. Poon MA, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991;1967-72.
23. Machover D, Goldschmidt E, Chollet P, Metzger G, Zittoun J, Marquet J, et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 1986;4:685-96.
24. Petrelli N, Herrera L, Rustum Y, Burke P, Creaven P, Stulc J, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987;5:1559-65.
25. Petrelli N, Douglass HO Jr., Herrera L, Russell D, Stablein DM, Bruckner HW, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989;7:1419-26.
26. de Gramont A, Krulik M, Cady J, Lagadec B, Maisani JE, Loiseau JP, et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 1988;24:1499-503.
27. Ardalan B, Chua L, Tian EM, Reddy R, Sridhar K, Benedetto, et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991;9:625-30.
28. Jäger E, Heike M, Bernhard H, Klein O, Bernhard G, Laute D, et al. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 1996;14:2274-9.
29. Borner MM, Bacchi M, Castigtione M, Weber W, Herrmann R, Fey MF, et al. 5-Fluorouracil with and without low-dose leucovorin for advanced colorectal carcinoma: a Swiss confirmatory Phase III trial [abstract]. Ann Oncol 1996; 7(Suppl):2100.
30. Buroker TR, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailliard JA, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:14-20.
31. Fried G, Tsalik M, Stein M, Dale J, Haim N. 5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study. Cancer Chemother Pharmacol 1995;35:437-40.
32. Petrioli R, Lorenzi M, Aquino A, Marsili S, Frediani B, Palazzuoli V, et al. Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care. Eur J Cancer 1995;31A:2105-8.
33. Johnson PW, Thompson PI, Seymour MT, Deasy NP, Thuraisingham RC, Slevin ML, et al. A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. Br J Cancer 1991;64:603-5.
34. Bécouarn YH, Brunet RC, Rouhier ML, Bussières EJ, Avril AR, Richaud PM, et al. High dose folinic acid and 5-fluorouracil bolus and continuous infusion for patients with advanced colorectal cancer. Cancer 1995;76:1126-31.
35. de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, et al. A prospectively randomized trial comparing 5FU bolus with low dose folinic acid (FUOLld) and 5FU bolus plus continuous infusion with high dose folinic acid (LV5FU2) for advanced colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1995;14:455.
36. de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, et al. A randomized trial comparing monthly low-dose leucovorin-5-fluorouracil bolus with bimonthly high-dose leucovorin-5-fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study (FFCD, GERCOD, SNFMI). J Clin Oncol 1997;15:808-15.
37. Beerblock K, Rinaldi T, André ID, Grange JD, Louvet C, Tournigand C, et al. Bi-weekly high-dose folinic acid (FA) and 5-fluorouracil (5FU) 48h-infusion in metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1996;15:490.
38. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995;13:1303-11.
39. Könne CH, Wilke H, Hecker H, Schoffski P, Kaufer C, Rauschecker H, et al. Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann Oncol 1995;6:461-6.
40. Machover D, Grison X, Goldschmidt E, Zittoun I, Lotz JP, Metzger G, et al. Fluorouracil combined with the [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study. J Nat Cancer Inst 1992;84:321-7.
41. Machover D, Grison X, Goldschmidt E, Zittoun J, Metzger G, Richard J, et al. 5-Fluorouracil combined with the [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study of two consecutive regimens. Ann Oncol 1993;4(Suppl 2):29-35.
42. Valsecchi R, Labianca R., Cascinu S, Barni S, Fiorentini G, Frontini L, et al. High dose (HD) versus low dose (LD) 1-leucovorin (ZLV) as a modulator of 5-days 5-fluorouracil (5FU) in advanced colorectal cancer (ACC): a "GISCAD" phase III study [abstract]. Proc Am Soc Clin Oncol 1995;14:457.
43. Erlichman C, Fine S, Kerr I, Hoffmann W, Gorg C, Schmoll HJ, et al. A phase II trial of 5-fluorouracil and l-leucovorin in patients with metastatic colorectal cancer. Am J Clin Oncol 1996;19:26-31.
44. Doroshow JH. Biochemical modulation of fluoropyrimidines: is there an optimal (6R,S) leucovorin dose and schedule? J Natl Cancer Inst 1996;88:393-5.
45. Jolivet J. Role of leucovorin dosing and administration schedule. Eur Cancer 1995;31A:1311-5.
46. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996;77:441-51.
47. Levi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992;69:893-900.